CDK9 inhibitors in cancer research. Issue 6 (16th May 2022)
- Record Type:
- Journal Article
- Title:
- CDK9 inhibitors in cancer research. Issue 6 (16th May 2022)
- Main Title:
- CDK9 inhibitors in cancer research
- Authors:
- Huang, Zhi
Wang, Tianqi
Wang, Cheng
Fan, Yan - Abstract:
- Abstract : This review outlines the representative CDK9 inhibitors in cancer research and application. Abstract : Cyclin dependent kinase 9 (CDK9) plays an essential role in regulating transcriptional elongation. Aberrations in CDK9 activity have been observed in various cancers, which make CDK9 an attractive therapeutic target for cancers. This led to an intensive development of small-molecule CDK9 inhibitors or new emerging strategies, such as proteolysis targeting chimeras (PROTACs). Here, we review the CDK9 modulators in cancer not only for research purposes, but also for therapeutic applications.
- Is Part Of:
- RSC medicinal chemistry. Volume 13:Issue 6(2022)
- Journal:
- RSC medicinal chemistry
- Issue:
- Volume 13:Issue 6(2022)
- Issue Display:
- Volume 13, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 13
- Issue:
- 6
- Issue Sort Value:
- 2022-0013-0006-0000
- Page Start:
- 688
- Page End:
- 710
- Publication Date:
- 2022-05-16
- Subjects:
- Pharmaceutical chemistry -- Periodicals
615.19005 - Journal URLs:
- http://www.rsc.org/ ↗
https://www.rsc.org/journals-books-databases/about-journals/rsc-medicinal-chemistry ↗ - DOI:
- 10.1039/d2md00040g ↗
- Languages:
- English
- ISSNs:
- 2632-8682
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8036.751550
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22107.xml